Average Co-Inventor Count = 2.39
ph-index = 15
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Sarepta Therapeutics, Inc. (23 from 122 patents)
2. The United States of America, As Represented by the Secretary, Department of Health and Human Services (5 from 3,539 patents)
3. University System of Maryland (5 from 1,934 patents)
4. The University of North Carolina at Chapel Hill (5 from 1,274 patents)
5. Progeria Research Foundation, Inc. (3 from 11 patents)
6. Isis Pharmaceuticals, Inc. (2 from 1,035 patents)
7. Avi Biopharma, Inc. (1 from 50 patents)
8. Santaris Pharma A/s (1 from 44 patents)
9. Ercole Biotech, Inc. (1 from 1 patent)
10. Ionis Pharmaceuticals, Inc. (271 patents)
29 patents:
1. 11802283 - Oligonucleotide analogues targeting human LMNA
2. 11236329 - Compound and method for treating myotonic dystrophy
3. 11071749 - Oligonucleotide analogues targeting human LMNA
4. 10927378 - Compound and method for treating myotonic dystrophy
5. 10822608 - Oligonucleotide analogues targeting human LMNA
6. 10398721 - Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
7. 10106796 - Compound and method for treating myotonic dystrophy
8. 10076536 - Oligonucleotide analogues targeting human LMNA
9. 9833468 - Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
10. 9682097 - Oligonucleotide analogues targeting human LMNA
11. 9453225 - Multiple exon skipping compositions for DMD
12. 9447416 - Multiple exon skipping compositions for DMD
13. 9447417 - Multiple exon skipping compositions for DMD
14. 9434948 - Multiple exon skipping compositions for DMD
15. 9326992 - Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA